Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TaiGen Biopharmaceuticals HoldingsROCO:4157 +0.34%59 Interest Coverage is 682.49 as of Dec. 2025, which is 93% below its 10-year median of 10,000.00. GuruFocus rates ROCO:4157 with a GF Score™ of 59/100 and a GF Value™ of NT$34.16 (Significantly Undervalued). Among 376 Biotechnology companies, TaiGen Biopharmaceuticals Holdings ranks worse than 59.04% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. TaiGen Biopharmaceuticals Holdings's
Operating Income
for the
three
months ended in Dec. 2025 was NT$187.7 Mil. TaiGen Biopharmaceuticals Holdings's Interest Expense for the
three
months ended in Dec. 2025 was NT$-0.3 Mil.
TaiGen Biopharmaceuticals Holdings's interest coverage for the quarter that ended in Dec. 2025 was 682.49.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for TaiGen Biopharmaceuticals Holdings's Interest Coverage or its related term are showing as below:
ROCO:4157'
s Interest Coverage Range Over the Past 10 Years
Min: 41.68 Med: No Debt Max: No Debt
Current: 41.68
ROCO:4157's Interest Coverage is ranked worse than 59.04% of 376
companies
in the Biotechnology industry
Industry Median: 104.025
vs ROCO:4157: 41.68
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
TaiGen Biopharmaceuticals Holdings Interest Coverage Related Terms
TaiGen Biopharmaceuticals Holdings Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ROCO:4157 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiGen Biopharmaceuticals Holdings Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's Interest Coverage distribution charts can be found below:
* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiGen Biopharmaceuticals Holdings (ROCO:4157) has a Interest Coverage of 682.49 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. This is 93% below median its historical median of 10,000.00. Over the past decade, TaiGen Biopharmaceuticals Holdings' Interest Coverage has ranged from 41.68 to 10,000.00. According to the industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #222 out of 376 companies in the Biotechnology industry, placing it in the top 59%.
Is TaiGen Biopharmaceuticals Holdings' Interest Coverage too high?
TaiGen Biopharmaceuticals Holdings' current Interest Coverage of 682.49 is 93% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 41.68 to a high of 10,000.00. The Biotechnology industry median Interest Coverage is 104.03. TaiGen Biopharmaceuticals Holdings' value of 682.49 is 556.1% above this industry median. Based on the distribution chart, TaiGen Biopharmaceuticals Holdings ranks #222 out of 376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, TaiGen Biopharmaceuticals Holdings has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiGen Biopharmaceuticals Holdings' Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #222 out of 376 companies for Interest Coverage. This places TaiGen Biopharmaceuticals Holdings in the lower half of its industry. The industry median Interest Coverage is 104.03. TaiGen Biopharmaceuticals Holdings' value of 682.49 is 556.1% above this benchmark. Historically, TaiGen Biopharmaceuticals Holdings' own Interest Coverage has ranged from 41.68 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 104.03, TaiGen Biopharmaceuticals Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TaiGen Biopharmaceuticals Holdings's current Interest Coverage of 682.49 is 556.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiGen Biopharmaceuticals Holdings's current Interest Coverage is 682.49, which is 93% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiGen Biopharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings (ROCO:4157) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$34.16, compared to a current price of NT$8.90 — trading 73.9% below its estimated fair value. The current Interest Coverage is 682.49, which is 93% below median its 10-year median of 10,000.00 and 556.1% above the Biotechnology industry median of 104.03. TaiGen Biopharmaceuticals Holdings' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For TaiGen Biopharmaceuticals Holdings (ROCO:4157), the current Interest Coverage is 682.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiGen Biopharmaceuticals Holdings (ROCO:4157) Overvalued in 2026?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings stock appears to be undervalued.
The current stock price of NT$8.90 is trading 73.9% below its estimated GF Value™ of NT$34.16.
GuruFocus considers TaiGen Biopharmaceuticals Holdings to be Significantly Undervalued.
Key valuation signals for ROCO:4157:
Interest Coverage: 682.49 (93% below median its 10-year median of 10,000.00)
GF Value™: NT$34.16 vs. price of NT$8.90 (73.9% below fair value)
Industry Position: 556.1% above the Biotechnology median (#222 of 376)
No single metric tells the full story. See the ROCO:4157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiGen Biopharmaceuticals Holdings Business Description
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
59GF Score
Get the complete analysis for ROCO:4157
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4157 has been successfully added to your 
